Suppr超能文献

尿外泌体能否作为前列腺癌治疗反应的标志物?

Can urinary exosomes act as treatment response markers in prostate cancer?

作者信息

Mitchell Paul J, Welton Joanne, Staffurth John, Court Jacquelyn, Mason Malcolm D, Tabi Zsuzsanna, Clayton Aled

机构信息

Section of Oncology & Palliative Medicine, School of Medicine, Cardiff University, Velindre Cancer Centre, Whitchurch, Cardiff, UK.

出版信息

J Transl Med. 2009 Jan 12;7:4. doi: 10.1186/1479-5876-7-4.

Abstract

BACKGROUND

Recently, nanometer sized vesicles (termed exosomes) have been described as a component of urine. Such vesicles may be a useful non-invasive source of markers in renal disease. Their utility as a source of markers in urological cancer remains unstudied. Our aim in this study was to investigate the feasibility and value of analysing urinary exosomes in prostate cancer patients undergoing standard therapy.

METHODS

Ten patients (with locally advanced PCa) provided spot urine specimens at three time points during standard therapy. Patients received 3-6 months neoadjuvant androgen deprivation therapy prior to radical radiotherapy, comprising a single phase delivering 55 Gy in 20 fractions to the prostate and 44 Gy in 20 fractions to the pelvic nodes. Patients were continued on adjuvant ADT according to clinical need. Exosomes were purified, and the phenotype compared to exosomes isolated from the prostate cancer cell line LNcaP. A control group of 10 healthy donors was included. Serum PSA was used as a surrogate treatment response marker. Exosomes present in urine were quantified, and expression of prostate markers (PSA and PSMA) and tumour-associated marker 5T4 was examined.

RESULTS

The quantity and quality of exosomes present in urine was highly variable, even though we handled all materials freshly and used methods optimized for obtaining highly pure exosomes. There was approx 2-fold decrease in urinary exosome content following 12 weeks ADT, but this was not sustained during radiotherapy. Nevertheless, PSA and PSMA were present in 20 of 24 PCa specimens, and not detected in healthy donor specimens. There was a clear treatment-related decrease in exosomal prostate markers in 1 (of 8) patient.

CONCLUSION

Evaluating urinary-exosomes remains difficult, given the variability of exosomes in urine specimens. Nevertheless, this approach holds promise as a non-invasive source of multiple markers of malignancy that could provide clinically useful information.

摘要

背景

最近,纳米级囊泡(称为外泌体)已被描述为尿液的一个组成部分。此类囊泡可能是肾脏疾病中一种有用的非侵入性标志物来源。它们作为泌尿系统癌症标志物来源的效用尚未得到研究。我们在本研究中的目的是调查分析接受标准治疗的前列腺癌患者尿液外泌体的可行性和价值。

方法

10例(局部晚期前列腺癌)患者在标准治疗期间的三个时间点提供随机尿液样本。患者在根治性放疗前接受3 - 6个月的新辅助雄激素剥夺治疗,包括一个阶段,向前列腺单次给予55 Gy,分20次进行,向盆腔淋巴结给予44 Gy,分20次进行。根据临床需要,患者继续接受辅助雄激素剥夺治疗。纯化外泌体,并将其表型与从前列腺癌细胞系LNcaP分离的外泌体进行比较。纳入10名健康供者作为对照组。血清前列腺特异性抗原(PSA)用作替代治疗反应标志物。对尿液中存在的外泌体进行定量,并检测前列腺标志物(PSA和前列腺特异性膜抗原[PSMA])和肿瘤相关标志物5T4的表达。

结果

尽管我们对所有材料都进行了新鲜处理,并使用了优化的方法来获得高纯度外泌体,但尿液中存在的外泌体的数量和质量变化很大。雄激素剥夺治疗12周后,尿液外泌体含量大约下降了2倍,但在放疗期间并未持续。然而,24份前列腺癌标本中有20份存在PSA和PSMA,而健康供者标本中未检测到。8名患者中有1名患者的外泌体前列腺标志物出现了与治疗相关的明显下降。

结论

鉴于尿液标本中外泌体的变异性,评估尿液外泌体仍然困难。然而,这种方法有望成为恶性肿瘤多种标志物的非侵入性来源,能够提供临床上有用的信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4799/2631476/d5ba9dc0252c/1479-5876-7-4-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验